WHO covid-19 drugs guideline: reconsider using convalescent plasma
BMJ
.
2022 Feb 8:376:o295.
doi: 10.1136/bmj.o295.
Authors
Nigel Paneth
1
,
Arturo Casadevall
2
,
Liise-Anne Pirofski
3
,
Jeffrey P Henderson
4
,
Brenda J Grossman
5
,
Shmuel Shoham
6
,
Michael J Joyner
7
Affiliations
1
Department of Epidemiology and Biostatistics, Michigan State University, Michigan, USA.
2
Department of Molecular Microbiology and Immunology, Johns Hopkins School of Public Health, Baltimore, Maryland, USA.
3
Albert Einstein College of Medicine, New York City, New York, USA.
4
Washington University School of Medicine, St Louis, Missouri, USA.
5
Department of Pathology and Immunology and Medicine, Washington University School of Medicine, St Louis, Missouri, USA.
6
Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.
7
Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota, USA.
PMID:
35135758
DOI:
10.1136/bmj.o295
No abstract available
Publication types
Letter
MeSH terms
COVID-19 / therapy*
COVID-19 Serotherapy
Guidelines as Topic
Humans
Immunization, Passive
Treatment Outcome*
World Health Organization